M&A | Partnerships

Legacy DBM expands and complements the Orthofix line of biologic solutions for spine and orthopedic surgical applications.

ORHub will enter the medical device market with biologics to regenerate cartilage and address degenerative disc disease and osteoarthritis.

StemCART is a preclinical Advanced Therapy Medical Product intended for the treatment of cartilage damage in patients worldwide.

The move will expand Isto's portfolio of procedure-specific allografts for spine, orthopedic and sports medicine applications.

The decision follows FDA's recent premarket approval of CartiHeal's Agili-C implant for the treatment of osteoarthritis.

genex Bone Graft Substitute has been upgraded with a new closed-mixing system and a comprehensive set of delivery options for U.S. market.

Bimini's Autopose family of products are designed for the harvesting and micro-fragmentation of adipose tissue.

curasan and Xlife Sciences formed Novaxomx to focus on development and marketing of therapies to treat musculoskeletal diseases and tissue regeneration.

Bone Biologics' rhNELL-1 bone graft substitute product will be supplied by MTF Biologics for the initiation and improvement of bone formation.

The new company will manage a portion of Seikagaku's pharmaceutical and medical device development in North America.